All In Biotech

Drug Trial Radar · NCT03786926

Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas

A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-689 in Patients With Relapsed or Refractory Lymphoma

Last checked: Nov 19, 2026Latest source record: Jun 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

53

Actual

Start

Aug 26, 2019

Primary completion

Jun 26, 2024

Study completion Jun 26, 2024

Sponsor

Lead sponsor
HutchmedIndustry
Sponsor type
Industry
First posted
Dec 26, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An open-label, dose escalation and expansion clinical trial to evaluate the safety, tolerability and PK of HMPL-689 in patients with relapsed or refractory lymphomas

Conditions

  • Lymphoma

Interventions

  • HMPL-689Drug

    HMPL-689 is a PI3Kδ inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Escalation Stage: Number of Patients With Dose-Limiting Toxicities (DLTs)Time frame: From the first dose of study drug (Day 1) up to Day 28 of Cycle 1 (each cycle is 28 days)
  2. Dose Escalation Stage: Number of Patients With Treatment-Emergent Adverse Events (TEAEs), Treatment Related Treatment-Emergent Adverse Events (TRAEs), Treatment-Emergent Serious Adverse Events (TESAEs) and Treatment Related Serious Adverse Events (TRSAEs)Time frame: From the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months
  3. Dose Expansion Stage: Number of Patients With Treatment-Emergent Adverse Events and Treatment Related Treatment-Emergent Adverse EventsTime frame: From the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 27 months

Locations

27 sites in 6 countries. Site status is shown where the registry gives one.

  • Innovative Clinical Research Institute

    Anaheim, California

  • Pacific Cancer Medical Center

    Anaheim, California

  • Ventura County Hematology-Oncology Specialists

    Oxnard, California

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia

  • Clinical Research Alliance, Inc

    Westbury, New York

  • Levine Cancer Institute- Atrium Health

    Charlotte, North Carolina

  • Baylor Scott and White Research Institute

    Dallas, Texas

  • Renovatio Clinical

    Houston, Texas

  • University of Texas Health Science Center at San Antonio

    San Antonio, Texas

  • Medical Oncology Associates, P.S.

    Spokane, Washington

  • Helsingin yliopistollinen keskussairaala

    Helsinki, Finland

  • Tampereen yliopistollinen sairaala

    Tampere, Finland

  • CHU de Nantes - Hotel Dieu

    Nantes, France

  • CHU de Bordeaux - Hôpital Haut-Lévêque

    Pessac, France

  • Hopital Henri Mondor

    Créteil, Val De Marne, France

  • Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi IRCCS

    Bologna, Italy

  • Ospedale San Raffaele

    Milan, Italy

  • KO-MED Centra Kliniczne

    Biała Podlaska, Poland

  • Uniwersyteckie Centrum Kliniczne

    Gdansk, Poland

  • BioResearch Group Sp. Z. o. o.

    Krakow, Poland

  • NASZ LEKARZ Osrodek Badan Klinicznych

    Torun, Poland

  • Uniwersytecki Szpital Kliniczny im. Jana Mikulicza Radeckiego

    Wroclaw, Poland

  • ICO Badalona - Hospital Universitari Germans Trias i Pujol

    Barcelona, Spain

  • ICO l'Hospitalet - Hospital Duran i Reynals

    Barcelona, Spain

  • Fundacion Jimenez Diaz

    Madrid, Spain

  • Hospital Universitario Virgen del Rocio

    Seville, Spain

  • Hospital Universitario Virgen Macarena

    Seville, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.